Salinomycin | CAS#53003-10-4 | CAS#55721-31-8 | antibacterial | Cancer

MedKoo Cat#: 406545 | Name: Salinomycin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Salinomycin is an antibacterial and coccidiostat ionophore agent. Salinomycin suppresses T24 cells by regulating KDM1A and the unfolded protein response pathway. Salinomycin alleviates osteoarthritis progression via inhibiting Wnt/β-catenin signaling. Vitamin D3 and Salinomycin synergy in MCF-7 cells cause cell death via endoplasmic reticulum stress in monolayer and 3D cell culture. Salinomycin induces cell cycle arrest and apoptosis and modulates hepatic cytochrome P450 mRNA expression in HepG2/C3a cells. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo,

Chemical Structure

Salinomycin

CAS#53003-10-4

Theoretical Analysis

MedKoo Cat#: 406545

Name: Salinomycin

CAS#: 53003-10-4

Chemical Formula: C42H70O11

Exact Mass: 750.4918

Molecular Weight: 751.01

Elemental Analysis: C, 67.17; H, 9.40; O, 23.43

Price and Availability

Size	Price	Availability
5mg	USD 250.00	Ready to Ship
10mg	USD 450.00	Ready to ship
25mg	USD 750.00	Ready to Ship
50mg	USD 1,250.00	Ready to Ship
100mg	USD 2,050.00	Ready to Ship
200mg	USD 3,450.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

AHR 3096; AHR3096; AHR-3096; HSDB 7032; HSDB7032; HSDB-7032; K 364; Salinomycin; BioCox; Sacox; Salocin; Coxistac.

IUPAC/Chemical Name

(R)-2-((2R,5S,6R)-6-((2S,3S,4S,6R)-6-((2S,5S,7R,9S,10S,12R,15R)-2-((2R,5R,6S)-5-ethyl-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl)-3-hydroxy-4-methyl-5-oxooctan-2-yl)-5-methyltetrahydro-2H-pyran-2-yl)butanoic acid

InChi Key

KQXDHUJYNAXLNZ-XQSDOZFQSA-N

InChi Code

InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1

SMILES Code

CC[C@@H](C(O)=O)[C@H]1CC[C@@H]([C@H]([C@H]([C@@H]([C@@H](C([C@@H]([C@H]2O[C@]3([C@@H](C[C@@H]2C)C)O[C@]4([C@@H](C=C3)O)CC[C@](O4)([C@H]5CC[C@](CC)([C@@H](O5)C)O)C)CC)=O)C)O)C)O1)C

Appearance

brown solid powder

Purity

98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

The ability of salinomycin to kill both CSCs and therapy-resistant cancer cells may define the compound as a novel and an effective anticancer drug. It has been also shown that Salinomycin and its derivatives exhibit potent antiproliferative activity against the drug-resistant cancer cell lines.

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A23T03K13

QC Data

View QC data: current batch, Lot#A23T03K13

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, selectively inhibits the growth of gram-positive bacteria.

In vitro activity:

The metastasis and invasion abilities of serum bladder cancer cell line T24 after salinomycin treatment in the experiment group were significantly reduced when compared with those in the control group, and the tumor metastasis lesions were decreased from an average of 1.59 to 0.6 (P < 0.05). Salinomycin can suppress the metastasis and invasion of bladder cancer cells, of which the mechanism is probably associated with the inhibition of EMT of tumor cells. Reference: Asian Pac J Trop Med. 2015 Jul;8(7):578-82. https://pubmed.ncbi.nlm.nih.gov/26276292/

In vivo activity:

The anti-tumor effect of Sal (Salinomycin) was further verified in vivo using the hepatoma orthotopic tumor model and the data obtained showed that the size of liver tumors in Sal-treated groups decreased compared to controls. Immunohistochemistry and TUNEL staining also demonstrated that Sal inhibits proliferation and induces apoptosis in vivo. Reference: PLoS One. 2012;7(12):e50638. https://pubmed.ncbi.nlm.nih.gov/23284640/

	Solvent	mg/mL	mM
Solubility
	DMF	20.0	26.63
	DMF:PBS (pH 7.2) (1:4)	0.2	0.27
	DMSO	47.2	62.89
	Ethanol	12.5	16.64

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 751.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Qu H, Ma B, Yuan HF, Wang ZY, Guo SJ, Zhang J. Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24. Asian Pac J Trop Med. 2015 Jul;8(7):578-82. doi: 10.1016/j.apjtm.2015.06.004. Epub 2015 Jul 9. PMID: 26276292. 2. Verdoodt B, Vogt M, Schmitz I, Liffers ST, Tannapfel A, Mirmohammadsadegh A. Salinomycin induces autophagy in colon and breast cancer cells with concomitant generation of reactive oxygen species. PLoS One. 2012;7(9):e44132. doi: 10.1371/journal.pone.0044132. Epub 2012 Sep 19. PMID: 23028492; PMCID: PMC3446972. 3. Klose J, Trefz S, Wagner T, Steffen L, Preißendörfer Charrier A, Radhakrishnan P, Volz C, Schmidt T, Ulrich A, Dieter SM, Ball C, Glimm H, Schneider M. Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. PLoS One. 2019 Feb 14;14(2):e0211916. doi: 10.1371/journal.pone.0211916. PMID: 30763370; PMCID: PMC6375586. 4. Wang F, He L, Dai WQ, Xu YP, Wu D, Lin CL, Wu SM, Cheng P, Zhang Y, Shen M, Wang CF, Lu J, Zhou YQ, Xu XF, Xu L, Guo CY. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 2012;7(12):e50638. doi: 10.1371/journal.pone.0050638. Epub 2012 Dec 20. PMID: 23284640; PMCID: PMC3527475.

In vitro protocol:

In vivo protocol:

1. Klose J, Trefz S, Wagner T, Steffen L, Preißendörfer Charrier A, Radhakrishnan P, Volz C, Schmidt T, Ulrich A, Dieter SM, Ball C, Glimm H, Schneider M. Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. PLoS One. 2019 Feb 14;14(2):e0211916. doi: 10.1371/journal.pone.0211916. PMID: 30763370; PMCID: PMC6375586. 2. Wang F, He L, Dai WQ, Xu YP, Wu D, Lin CL, Wu SM, Cheng P, Zhang Y, Shen M, Wang CF, Lu J, Zhou YQ, Xu XF, Xu L, Guo CY. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 2012;7(12):e50638. doi: 10.1371/journal.pone.0050638. Epub 2012 Dec 20. PMID: 23284640; PMCID: PMC3527475.

1: Anees M, Gupta P, Kaur H, Kharbanda S, Singh H. Concomitant Delivery of Pirarubicin and Salinomycin Synergistically Enhanced the Efficacy of Cancer Therapy and Reduced the Risk of Cancer Relapse. AAPS PharmSciTech. 2024 Sep 7;25(7):211. doi: 10.1208/s12249-024-02918-3. PMID: 39242397. 2: Chen YJ, Guo ZT, Chen HQ, Zhang SF, Bao YX, Xie Z, Ke JL, Ye WJ, Liang JC, Chen JC, Li N, Zheng FX, Liao H, Wu T, Pang JX. Salinomycin, a potent inhibitor of XOD and URAT1, ameliorates hyperuricemic nephropathy by activating NRF2, modulating the gut microbiota, and promoting SCFA production. Chem Biol Interact. 2024 Aug 31;403:111220. doi: 10.1016/j.cbi.2024.111220. Epub ahead of print. PMID: 39222901. 3: Hamdi S, Míguez-González A, Cela-Dablanca R, Barreiro A, Fernández-Sanjurjo MJ, Núñez-Delgado A, Álvarez-Rodríguez E. Natural and modified clays as low-cost and ecofriendly materials to remove salinomycin from environmental compartments. J Environ Manage. 2024 Sep;368:122158. doi: 10.1016/j.jenvman.2024.122158. Epub 2024 Aug 15. PMID: 39151338. 4: Cheng Y, Xiao S, Lan L, Liu D, Tang R, Gu J, Ma L, He Z, Chen X, Geng L, Chen P, Li H, Ren L, Zhu Y, Cheng Y, Gong S. WNT2B high‑expressed fibroblasts induce the fibrosis of IBD by promoting NK cells secreting IL-33. J Mol Med (Berl). 2024 Oct;102(10):1199-1215. doi: 10.1007/s00109-024-02477-x. Epub 2024 Aug 13. PMID: 39138828. 5: Biabani N, Taherpour K, Ghasemi HA, Akbari Gharaei M, Hafizi M, Nazaran MH. Dietary advanced chelate technology-based 7-mineral supplement improves growth performance and intestinal health indicators during a mixed Eimeria challenge in broiler chickens. Vet Parasitol. 2024 Oct;331:110277. doi: 10.1016/j.vetpar.2024.110277. Epub 2024 Jul 31. PMID: 39094330. 6: Hao C, Chen P, Setrerrahmane S, Xu H. A peptide-salinomycin conjugate with a bystander effect reduces the stemness characteristics of ovarian cancer cells and enhances drug sensitivity. Eur J Med Chem. 2024 Oct 5;276:116701. doi: 10.1016/j.ejmech.2024.116701. Epub 2024 Jul 20. PMID: 39067438. 7: Alhajamee M, Khalaj-Kondori M, Babaei E, Mahdavi M. A biochemical assessment of apoptosis-inducing impact of Salinomycin in combination with ciprofloxacin on human leukemia KG1-a stem-like cells in the presence and absence of insulin. Mol Biol Rep. 2024 Jul 13;51(1):807. doi: 10.1007/s11033-024-09768-z. PMID: 39002036. 8: van Dongen KCW, de Lange E, van Asseldonk LLM, Zoet L, van der Fels-Klerx HJ. Safety and transfer of veterinary drugs from substrate to black soldier fly larvae. Animal. 2024 Jul;18(7):101214. doi: 10.1016/j.animal.2024.101214. Epub 2024 Jun 13. PMID: 38970990. 9: Dang R, Yang Y, Wang L, Zhen K, Wen J, Tan J, Feng J. Exploring the Role of the Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma Migration and Tumor Angiogenesis. Altern Ther Health Med. 2024 Jun 28:AT10934. Epub ahead of print. PMID: 38940798. 10: Fang J, Gerschel P, Singh K, Apfel UP, Suntharalingam K. Cobalt(III)-Macrocyclic Scaffolds with Anti-Cancer Stem Cell Activity. Molecules. 2024 Jun 8;29(12):2743. doi: 10.3390/molecules29122743. PMID: 38930809; PMCID: PMC11206342. 11: Saddoris-Clemons K, Osho S, Garcia M, Humphrey B. Effects of Dietary Inclusion of a Proprietary Combination of Quillaja saponaria and Yucca schidigera on Intestinal Permeability and Immune Response in Broiler Chickens during a Coccidia Challenge. Animals (Basel). 2024 Jun 8;14(12):1737. doi: 10.3390/ani14121737. PMID: 38929356; PMCID: PMC11200908. 12: Abroon S, Nouri M, Mahdavi M. Hesperidin/Salinomycin Combination; a Natural Product for Deactivation of the PI3K/Akt Signaling Pathway and Anti-Apoptotic Factors in KG1a Cells. J Fluoresc. 2024 Jun 25. doi: 10.1007/s10895-024-03808-4. Epub ahead of print. PMID: 38916633. 13: Spišáková D, Kožárová I, Hriciková S, Marcinčák S. Comprehensive Screening of Salinomycin in Feed and Its Residues in Poultry Tissues Using Microbial Inhibition Tests Coupled to Enzyme-Linked Immunosorbent Assay (ELISA). Foods. 2024 May 25;13(11):1661. doi: 10.3390/foods13111661. PMID: 38890889; PMCID: PMC11171941. 14: Fan C, Wu H, Du X, Li C, Zeng W, Qu L, Cang C. Inhibition of lysosomal TRPML1 channel eliminates breast cancer stem cells by triggering ferroptosis. Cell Death Discov. 2024 May 27;10(1):256. doi: 10.1038/s41420-024-02026-y. PMID: 38802335; PMCID: PMC11130215. 15: Ochiai Y, Suzuki-Karasaki M, Ando T, Suzuki-Karasaki M, Nakayama H, Suzuki- Karasaki Y. Nitric oxide-dependent cell death in glioblastoma and squamous cell carcinoma via prodeath mitochondrial clustering. Eur J Cell Biol. 2024 Jun;103(2):151422. doi: 10.1016/j.ejcb.2024.151422. Epub 2024 May 18. PMID: 38795505. 16: EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP); Bampidis V, Azimonti G, Bastos ML, Christensen H, Durjava M, Dusemund B, Kouba M, López-Alonso M, Puente SL, Marcon F, Mayo B, Pechová A, Petkova M, Ramos F, Villa RE, Woutersen R, Bories G, Brantom P, Cocconcelli PS, Finizio A, Gropp J, Poiger T, Rychen G, Teodorovic I, Galobart J, Navarro-Villa A, Pettenati E, Rossi B, Vettori MV, Holczknecht O. Safety and efficacy of a feed additive consisting of salinomycin sodium (Sacox®) for rabbits for fattening (Huvepharma N.V.). EFSA J. 2024 May 23;22(5):e8796. doi: 10.2903/j.efsa.2024.8796. PMID: 38784844; PMCID: PMC11112458. 17: Kanchan S, Marwaha D, Tomar B, Agrawal S, Mishra S, Kapoor R, Sushma, Jha G, Sharma D, Bhatta RS, Mishra PR, Rath SK. Nanocarrier - Mediated Salinomycin Delivery Induces Apoptosis and Alters EMT Phenomenon in Prostate Adenocarcinoma. AAPS PharmSciTech. 2024 May 9;25(5):104. doi: 10.1208/s12249-024-02817-7. PMID: 38724836. 18: Xue W, Zhu B, Zhao K, Huang Q, Luo H, Shou Y, Huang Z, Guo H. Targeting LRP6: A new strategy for cancer therapy. Pharmacol Res. 2024 Jun;204:107200. doi: 10.1016/j.phrs.2024.107200. Epub 2024 May 6. PMID: 38710241. 19: Markowska A, Kojs Z, Twardawa D, Pietras J, Markowska J. Selected markers of ovarian cancer and their relation to targeted therapy (Review). Exp Ther Med. 2024 Mar 27;27(5):236. doi: 10.3892/etm.2024.12523. PMID: 38628658; PMCID: PMC11019661. 20: Wang Y, Li C, Jiang T, Yin Y, Wang Y, Zhao H, Yu L. A comprehensive exploration of twist1 to identify a biomarker for tumor immunity and prognosis in pan-cancer. Medicine (Baltimore). 2024 Apr 12;103(15):e37790. doi: 10.1097/MD.0000000000037790. PMID: 38608058; PMCID: PMC11018223.